Dr. Reddy’s launches palbociclib to widen access to high-quality breast cancer drug
HYDERABAD: Dr. Reddy’s Laboratories Ltd. has on Friday announced that it has acquired the trademark rights of the breast cancer drug PRIMCYV® from Pfizer Products India Pvt Ltd for use in the Indian market.
PRIMCYV® is a targeted therapy containing the active constituent palbociclib, a first-in-class CDK 4/6 inhibitor indicated in combination with an aromatase inhibitor for the first-line treatment of adult patients with HR+, HER2- metastatic breast cancer.
Dr. Reddy’s in collaboration with Pfizer Products India has been marketing the drug which comes in the form of hard capsules in strengths of 75 mg, 100 mg and 125 mg under the brand name PRIMCYV® in India since May 2022.
Following the trademark rights acquisition, Dr. Reddy’s will manufacture the Active Pharmaceutical Ingredient (API) and finished drug at its state-of-the-art facilities approved by the United States Food and Drug Administration (USFDA). Dr. Reddy’s is amongst select companies in the world to have conducted a bioequivalence study and received tentative approval from the USFDA for palbociclib. The in-house product will be retailed in the Indian market at a reduction of 85% from the current MRP to increase affordability and access to palbociclib. Dr. Reddy’s plans to roll out a unique Patient Assistance Programme to support long-term therapy of the patients on PRIMCYV®.
Through leading brands such as Hervycta, Mitotax, Docetere, Nab Mitotax, PRIMCYV and others, Dr. Reddy’s has made a portfolio of reliable and high-quality medicines available to patients in India in keeping with its purpose of ‘Good Health Can’t Wait’.
